Search

Your search keyword '"Wieringa, Jantien W."' showing total 33 results
Start Over Author "Wieringa, Jantien W."
33 results on '"Wieringa, Jantien W."'

1. Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy

Author

Korgaard, Julie, Vestergaard, Thea, Lystbæk, Uffe Lund, Berg, Anne, Mikkelsen, Anette Tyrsted, Holm, Anne Marie, Hansen, Annebirthe Bo, Mathiesen, Ole, Jensen, Jette Krüger, Neumann, Lone, Boris, Jane, Lemming, Marianne, Rahbek, Marianne, Søresen, Heidi Gram, Storkholm, Marie Højriis, Ziska, Jeanette, Vestergaard, Else Marie, Bøggild Ipsen, Sidsel Elisabeth, Gram, Jørgen, Brixen, Gunhild, Westergaard, Hanne Brix, Friis-Hansen, Lennart Jan, Olsen, Bettina Friis, Fischer, Heidi, Bjerrum, Poul Jannik, Ibsen, Anne Haahr, Jaeger, Vibeke, Madsen, Jesper Clausager, Møller, Lars Alling, Søeby, Karen, Damm, Jane Hansen, Hilsted, Linda, Christiansen, Lone, Sharif, Heidi, Johansen, Britt Strøm, Dahl, Karina Mattebjerg, Langholz, Ebbe, Kamstrup, Pia R., Jochumsen, Anja, Huusom, Lene Drasbek, Bathum, Lise, Wilken-Jensen, Charlotte, Julsgaard, Mette, Wieringa, Jantien W., Baunwall, Simon M.D., Bibby, Bo M., Driessen, Gertjan J.A., Kievit, Linda, Brodersen, Jacob B., Poulsen, Anja, Kjeldsen, Jens, Hansen, Mette M., Tang, Hai Q., Balmer, Christina L., Glerup, Henning, Seidelin, Jakob B., Haderslev, Kent V., Svenningsen, Lise, Wildt, Signe, Juel, Mie A., Neumann, Anders, Fuglsang, Jens, Jess, Tine, Haase, Anne-Mette, Hvas, Christian L., Kelsen, Jens, and Janneke van der Woude, C.

Published
2025
Full Text
View/download PDF

2. Serum proteomics reveals hemophagocytic lymphohistiocytosis-like phenotype in a subset of patients with multisystem inflammatory syndrome in children

Author

Tulling, Adam J., Holierhoek, Marloes G., Jansen-Hoogendijk, Anja M., Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J., Oostenbrink, Rianne, Buysse, Corinne M.P., Bannier, Michiel A.G.E., Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C., Jacobs, Monique A.M., Kamps, Arvid W.A., van der Linden, Jan W., Lebon, Ankie, Oudshoorn, Johanna H., Tramper-Stranders, Gerdien A., Vastert, Sebastiaan J., Wieringa, Jantien W., Terheggen-Lagro, Suzanne W.J., Wildenbeest, Joanne G., von Asmuth, Erik G.J., van den Akker, Erik B., van Gijn, Marielle E., Lugthart, Gertjan, and Buddingh, Emilie P.

Published
2024
Full Text
View/download PDF

3. Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy

Author

Julsgaard, Mette, Wieringa, Jantien W., Baunwall, Simon M.D., Bibby, Bo M., Driessen, Gertjan J.A., Kievit, Linda, Brodersen, Jacob B., Poulsen, Anja, Kjeldsen, Jens, Hansen, Mette M., Tang, Hai Q., Balmer, Christina L., Glerup, Henning, Seidelin, Jakob B., Haderslev, Kent V., Svenningsen, Lise, Wildt, Signe, Juel, Mie A., Neumann, Anders, Fuglsang, Jens, Jess, Tine, Haase, Anne Mette, Hvas, Christian L., Kelsen, Jens, Janneke van der Woude, C., Lystbæk, Uffe Lund, Julsgaard, Mette, Wieringa, Jantien W., Baunwall, Simon M.D., Bibby, Bo M., Driessen, Gertjan J.A., Kievit, Linda, Brodersen, Jacob B., Poulsen, Anja, Kjeldsen, Jens, Hansen, Mette M., Tang, Hai Q., Balmer, Christina L., Glerup, Henning, Seidelin, Jakob B., Haderslev, Kent V., Svenningsen, Lise, Wildt, Signe, Juel, Mie A., Neumann, Anders, Fuglsang, Jens, Jess, Tine, Haase, Anne Mette, Hvas, Christian L., Kelsen, Jens, Janneke van der Woude, C., and Lystbæk, Uffe Lund

Published
2025

4. Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children From Wild-type to Population Immunity: A Prospective Multicenter Cohort Study With Real-time Reporting

Author

Tulling, Adam J., Lugthart, Gertjan, Mooij, Miriam G., Brackel, Caroline L. H., Terheggen-Lagro, Suzanne W. J., Oostenbrink, Rianne, Buysse, Corinne M. P., Hashimoto, Simone, Armbrust, Wineke, Bannier, Michiel A. G. E., Bekhof, Jolita, van Gameren-Oosterom, Helma B., Hendriks, Han, van Houten, Marlies A., van der Linden, Jan W., Lebon, Ankie, van Onzenoort-Bokken, Lonneke, Tramper-Stranders, Gerdien A., van Veen, Mirjam, von Asmuth, Erik G. J., Buddingh, Emilie P., van der Aa, Leontien B., van Aerde, Koen J., Auffarth-Smedema, Bettina, Bart, Ingeborg Y., Beek, Cherise, Bechan, Gitanjali I., van den Berg, J. Merlijn, Boonstra, Venje H., Breukels, Mijke, Brinkman, Danielle M.C., Bruijning-Verhagen, Patricia C.J.L., de Crom, Stephanie C., Ernst-Kruis, Margot R., Fraaij, Pieter L.A., Goris, Joyce, Groeneweg, Michael, Gruppen, Mariken, Hammer, Sanne C., Hissink Muller, Petra C.E., Homan-van der Veen, Jenneke, Jacobs, Monique A.M., Kamps, Arvid W.A., Ketharanathan, Naomi, van der Kuip, Martijn, Kuijpers, Taco W., Legger, Elizabeth G., Lo-A-Njoe, Shirley, Manshande, Meindert E., Miedema, Carien J., Obihara, Charlie C., Olivieira, Gideon O., Oudshoorn, Annemarie, Peeters, Esther J.E., Petru, Ronald, Pijnenburg, Marielle W.H., Rook, Denise, Schilleman, Kim, Schopmeijer, Rian, Slotboom, David, van der Steen, Manouk, Stol, Kim, Thomasse, Yolande E.M., Tissing, Wim J.E., van den Tweel, Xandra W., Vastert, Sebastiaan J., Verbeek, Anne B., Vernooij-van Langen, Annette M.M., Wieringa, Jantien W., Wildenbeest, Joanne G., de Wildt, Saskia N., and van Woerden, Christiaan

Published
2023
Full Text
View/download PDF

7. Serum proteomics reveals hemophagocytic lymphohistiocytosis-like phenotype in a subset of patients with multisystem inflammatory syndrome in children

Author

CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Genetica Sectie Genoomdiagnostiek, Tulling, Adam J, Holierhoek, Marloes G, Jansen-Hoogendijk, Anja M, Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J, Oostenbrink, Rianne, Buysse, Corinne M P, Bannier, Michiel A G E, Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C, Jacobs, Monique A M, Kamps, Arvid W A, van der Linden, Jan W, Lebon, Ankie, Oudshoorn, Johanna H, Tramper-Stranders, Gerdien A, Vastert, Sebastiaan J, Wieringa, Jantien W, Terheggen-Lagro, Suzanne W J, Wildenbeest, Joanne G, von Asmuth, Erik G J, van den Akker, Erik B, van Gijn, Marielle E, Lugthart, Gertjan, Buddingh, Emilie P, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Genetica Sectie Genoomdiagnostiek, Tulling, Adam J, Holierhoek, Marloes G, Jansen-Hoogendijk, Anja M, Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J, Oostenbrink, Rianne, Buysse, Corinne M P, Bannier, Michiel A G E, Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C, Jacobs, Monique A M, Kamps, Arvid W A, van der Linden, Jan W, Lebon, Ankie, Oudshoorn, Johanna H, Tramper-Stranders, Gerdien A, Vastert, Sebastiaan J, Wieringa, Jantien W, Terheggen-Lagro, Suzanne W J, Wildenbeest, Joanne G, von Asmuth, Erik G J, van den Akker, Erik B, van Gijn, Marielle E, Lugthart, Gertjan, and Buddingh, Emilie P

Published
2024

9. Infant ustekinumab Clearance, Risk of Infection, and Development after exposure during pregnancy

Author

Julsgaard, Mette, primary, Wieringa, Jantien W., additional, Baunwall, Simon M.D., additional, Bibby, Bo M., additional, Driessen, Gertjan J.A., additional, Kievit, Linda, additional, Brodersen, Jacob B., additional, Poulsen, Anja, additional, Kjeldsen, Jens, additional, Hansen, Mette M., additional, Tang, Hai Q., additional, Balmer, Christina L., additional, Glerup, Henning, additional, Seidelin, Jakob B., additional, Haderslev, Kent V., additional, Svenningsen, Lise, additional, Wildt, Signe, additional, Juel, Mie A., additional, Neumann, Anders, additional, Fuglsang, Jens, additional, Jess, Tine, additional, Hasse, Anne-Mette, additional, Hvas, Christian L., additional, Kelsen, Jens, additional, and Janneke van der Woude, C., additional

Published
2024
Full Text
View/download PDF

11. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns)

Author

Bakry, A, Dutta, S, el Helou, S, Kalaniti, K, Pogorzelski, D, Alliston, S, Roy, M, Grey, V, Hauff, K, Hill, S, Kittanakom, S, Janota, J, Visnovska, M, Fontana, M, Lanz, N, Stocker, M, Glauser, D, Zimmerman, U, Tomaske, M, Nelle, M, Schlapbach, LJ, Schuerman, FABA, Sie, SD, van Weissenbruch, MM, van den Dungen, FAM, Strik, M, van den Tooren-de, HK, van Rossum, Groot A, Batstra, M, van der Meer-Kappelle, LH, de Vries, E, de Mol, AC, Bolt-Wieringa, J, Stok, Daniel, Moonen, R, Donker, S, van Gijsel, J, Gondriet, IPE, van Herk, W, Hoekstein, S, Hofhuis, M, Hop, W, de Ligt, L, Manai, B, Kornelisse, R, de Rijke, Y, van Rossum, A, Siiskonen, S, van der Velden, J, Visser, EG, van Wijk, J Asch, Willemsen, S, van der Geijn, GJ, Haringsma, A, Andriessen, PA, Broeren, MAC, Donker, A, Stocker, Martin, van Herk, Wendy, el Helou, Salhab, Dutta, Sourabh, Fontana, Matteo S, Schuerman, Frank A B A, van den Tooren-de Groot, Rita K, Wieringa, Jantien W, Janota, Jan, van der Meer-Kappelle, Laura H, Moonen, Rob, Sie, Sintha D, de Vries, Esther, Donker, Albertine E, Zimmerman, Urs, Schlapbach, Luregn J, de Mol, Amerik C, Hoffman-Haringsma, Angelique, Roy, Madan, Tomaske, Maren, Kornelisse, René F, van Gijsel, Juliette, Visser, Eline G, Willemsen, Sten P, and van Rossum, Annemarie M C

Published
2017
Full Text
View/download PDF

12. Validation of the Pharmacokinetic Model for Anti-TNFα Clearance in Infants Exposed to Anti-TNFα During Pregnancy.

Author

Wieringa, Jantien W, Kruizinga, Matthijs D, Driessen, Gertjan J A, Woude, C Janneke van der, and Julsgaard, Mette

Abstract

Background and Aims The ECCO guideline recommends postponing live attenuated vaccines in infants exposed to anti-tumour necrosis factor alpha [anti-TNFα] in utero until drug clearance. The aim was to validate the predictive performance of the anti-TNFα clearance model. Methods Newborns and data for anti-TNFα concentrations from the prospective PETIT cohort were included. The anti-TNFα clearance model was used to predict all measured concentrations in the PETIT cohort, based on the measured cord blood concentration and the mean population clearance described in the model. Bayesian maximum a posteriori optimization was used to estimate the use of drug monitoring. Predictive capability and drug monitoring were assessed through mean absolute error [MAE], root mean squared prediction error, and limits of agreement according to Bland and Altman. Results Observed drug concentrations after birth were within the 80% prediction interval in 94% of adalimumab samples and 93% of infliximab samples. The anti-TNFα clearance model accurately predicted the concentration at 6 months after birth with an MAE of 0.03 µg/mL [SD 0.03] for adalimumab and 0.11 µg/mL [SD 0.18] for infliximab based on cord blood concentrations. Addition of an additional sample between 1 and 4 months after birth improved the predictive accuracy for infliximab (MAE 0.05 [SD 0.09]) but not for adalimumab. Guidance for use in clinical practice was formulated. Conclusions The validity of the anti-TNFα clearance model is high, and hence can be used to guide clinicians regarding the timing of live vaccines in infants exposed to adalimumab or infliximab in utero. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children from Wild-type to Population Immunity: A Prospective Multicenter Cohort Study with Real-time Reporting

Author

Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Infectieziekten patientenzorg, Infectieziekten onderzoek2 (Wildenbeest), Tulling, Adam J., Lugthart, Gertjan, Mooij, Miriam G., Brackel, Caroline L.H., Terheggen-Lagro, Suzanne W.J., Oostenbrink, Rianne, Buysse, Corinne M.P., Hashimoto, Simone, Armbrust, Wineke, Bannier, Michiel A.G.E., Bekhof, Jolita, Van Gameren-Oosterom, Helma B., Hendriks, Han, Van Houten, Marlies A., Van Der Linden, Jan W., Lebon, Ankie, Van Onzenoort-Bokken, Lonneke, Tramper-Stranders, Gerdien A., Van Veen, Mirjam, Von Asmuth, Erik G.J., Buddingh, Emilie P., Van Der Aa, Leontien B., Van Aerde, Koen J., Auffarth-Smedema, Bettina, Bart, Ingeborg Y., Beek, Cherise, Bechan, Gitanjali I., Van Den Berg, J. Merlijn, Boonstra, Venje H., Breukels, Mijke, Brinkman, Danielle M.C., Bruijning-Verhagen, Patricia C.J.L., De Crom, Stephanie C., Ernst-Kruis, Margot R., Fraaij, Pieter L.A., Goris, Joyce, Groeneweg, Michael, Gruppen, Mariken, Hammer, Sanne C., Hissink Muller, Petra C.E., Homan-Van Der Veen, Jenneke, Jacobs, Monique A.M., Kamps, Arvid W.A., Ketharanathan, Naomi, Van Der Kuip, Martijn, Kuijpers, Taco W., Legger, Elizabeth G., Lo-A-Njoe, Shirley, Manshande, Meindert E., Miedema, Carien J., Obihara, Charlie C., Olivieira, Gideon O., Oudshoorn, Annemarie, Peeters, Esther J.E., Petru, Ronald, Pijnenburg, Marielle W.H., Rook, Denise, Schilleman, Kim, Schopmeijer, Rian, Slotboom, David, Van Der Steen, Manouk, Stol, Kim, Thomasse, Yolande E.M., Tissing, Wim J.E., Van Den Tweel, Xandra W., Vastert, Sebastiaan J., Verbeek, Anne B., Vernooij-Van Langen, Annette M.M., Wieringa, Jantien W., Wildenbeest, Joanne G., De Wildt, Saskia N., Van Woerden, Christiaan, Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Infectieziekten patientenzorg, Infectieziekten onderzoek2 (Wildenbeest), Tulling, Adam J., Lugthart, Gertjan, Mooij, Miriam G., Brackel, Caroline L.H., Terheggen-Lagro, Suzanne W.J., Oostenbrink, Rianne, Buysse, Corinne M.P., Hashimoto, Simone, Armbrust, Wineke, Bannier, Michiel A.G.E., Bekhof, Jolita, Van Gameren-Oosterom, Helma B., Hendriks, Han, Van Houten, Marlies A., Van Der Linden, Jan W., Lebon, Ankie, Van Onzenoort-Bokken, Lonneke, Tramper-Stranders, Gerdien A., Van Veen, Mirjam, Von Asmuth, Erik G.J., Buddingh, Emilie P., Van Der Aa, Leontien B., Van Aerde, Koen J., Auffarth-Smedema, Bettina, Bart, Ingeborg Y., Beek, Cherise, Bechan, Gitanjali I., Van Den Berg, J. Merlijn, Boonstra, Venje H., Breukels, Mijke, Brinkman, Danielle M.C., Bruijning-Verhagen, Patricia C.J.L., De Crom, Stephanie C., Ernst-Kruis, Margot R., Fraaij, Pieter L.A., Goris, Joyce, Groeneweg, Michael, Gruppen, Mariken, Hammer, Sanne C., Hissink Muller, Petra C.E., Homan-Van Der Veen, Jenneke, Jacobs, Monique A.M., Kamps, Arvid W.A., Ketharanathan, Naomi, Van Der Kuip, Martijn, Kuijpers, Taco W., Legger, Elizabeth G., Lo-A-Njoe, Shirley, Manshande, Meindert E., Miedema, Carien J., Obihara, Charlie C., Olivieira, Gideon O., Oudshoorn, Annemarie, Peeters, Esther J.E., Petru, Ronald, Pijnenburg, Marielle W.H., Rook, Denise, Schilleman, Kim, Schopmeijer, Rian, Slotboom, David, Van Der Steen, Manouk, Stol, Kim, Thomasse, Yolande E.M., Tissing, Wim J.E., Van Den Tweel, Xandra W., Vastert, Sebastiaan J., Verbeek, Anne B., Vernooij-Van Langen, Annette M.M., Wieringa, Jantien W., Wildenbeest, Joanne G., De Wildt, Saskia N., and Van Woerden, Christiaan

Published
2023

14. Increase in Invasive Group a Streptococcal Infections in Children in the Netherlands, A Survey Among 7 Hospitals in 2022

Author

Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Van Kempen, Evelien B., Bruijning-Verhagen, Patricia C.J., Borensztajn, Dorine, Vermont, Clementien L., Quaak, Marjolijn S.W., Janson, Jo Anne, Maat, Ianthe, Stol, Kim, Vlaminckx, Bart J.M., Wieringa, Jantien W., Van Sorge, Nina M., Boeddha, Navin P., Van Veen, Mirjam, Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Van Kempen, Evelien B., Bruijning-Verhagen, Patricia C.J., Borensztajn, Dorine, Vermont, Clementien L., Quaak, Marjolijn S.W., Janson, Jo Anne, Maat, Ianthe, Stol, Kim, Vlaminckx, Bart J.M., Wieringa, Jantien W., Van Sorge, Nina M., Boeddha, Navin P., and Van Veen, Mirjam

Published
2023

17. INCREASE IN INVASIVE GROUP A STREPTOCOCCAL INFECTIONS IN CHILDREN IN THE NETHERLANDS, A SURVEY AMONG 7 HOSPITALS IN 2022

Author

van Kempen, Evelien B., primary, Bruijning-Verhagen, Patricia C.J., additional, Borensztajn, Dorine, additional, Vermont, Clementien L., additional, Quaak, Marjolijn S.W., additional, Janson, Jo-Anne, additional, Maat, Ianthe, additional, Stol, Kim, additional, Vlaminckx, Bart J.M., additional, Wieringa, Jantien W., additional, van Sorge, Nina M., additional, Boeddha, Navin P., additional, and van Veen, Mirjam, additional

Published
2022
Full Text
View/download PDF

18. Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and Management

Author

Luck, Suzanne E., Wieringa, Jantien W., Blázquez-Gamero, Daniel, Henneke, Philipp, Schuster, Katharina, Butler, Karina, Capretti, Maria Grazia, Cilleruelo, Maria José, Curtis, Nigel, Garofoli, Francesca, Heath, Paul, Iosifidis, Elias, Klein, Nigel, Lombardi, Giuseppina, Lyall, Hermione, Nieminen, Tea, Pajkrt, Dasja, Papaevangelou, Vassiliki, Posfay-Barbe, Klara, Puhakka, Laura, Roilides, Emmanuel, Rojo, Pablo, Saavedra-Lozano, Jesús, Shah, Teshri, Sharland, Mike, Saxen, Harri, and Vossen, Ann C.T.M

Published
2017
Full Text
View/download PDF

19. Machine learning used to compare the diagnostic accuracy of risk factors, clinical signs and biomarkers and to develop a new prediction model for neonatal early-onset sepsis

Author

Stocker, Martin, Daunhawer, Imant, Van Herk, Wendy, El Helou, Salhab, Dutta, Sourabh, Schuerman, Frank A. B. A., Van Den Tooren-de Groot, Rita K., Wieringa, Jantien W., Janota, Jan, Van Der Meer-Kappelle, Laura H., Moonen, Rob, Sie, Sintha D., De Vries, Esther, Donker, Albertine E., Zimmerman, Urs, Schlapbach, Luregn J., De Mol, Amerik C., Hoffmann-Haringsma, Angelique, Roy, Madan, Tomaske, Maren, Kornelisse, René F., Van Gijsel, Juliette, Plötz, Frans B., Wellmann, Sven, Achten, Niek B., Lehnick, Dirk, Van Rossum, Annemarie M. C., Vogt, Julia E., Stocker, Martin, Daunhawer, Imant, Van Herk, Wendy, El Helou, Salhab, Dutta, Sourabh, Schuerman, Frank A. B. A., Van Den Tooren-de Groot, Rita K., Wieringa, Jantien W., Janota, Jan, Van Der Meer-Kappelle, Laura H., Moonen, Rob, Sie, Sintha D., De Vries, Esther, Donker, Albertine E., Zimmerman, Urs, Schlapbach, Luregn J., De Mol, Amerik C., Hoffmann-Haringsma, Angelique, Roy, Madan, Tomaske, Maren, Kornelisse, René F., Van Gijsel, Juliette, Plötz, Frans B., Wellmann, Sven, Achten, Niek B., Lehnick, Dirk, Van Rossum, Annemarie M. C., and Vogt, Julia E.

Abstract

Background: Current strategies for risk stratification and prediction of neonatal early-onset sepsis (EOS) are inefficient and lack diagnostic performance. The aim of this study was to use machine learning to analyze the diagnostic accuracy of risk factors (RFs), clinical signs and biomarkers and to develop a prediction model for culture-proven EOS. We hypothesized that the contribution to diagnostic accuracy of biomarkers is higher than of RFs or clinical signs. Study Design: Secondary analysis of the prospective international multicenter NeoPInS study. Neonates born after completed 34 weeks of gestation with antibiotic therapy due to suspected EOS within the first 72 hours of life participated. Primary outcome was defined as predictive performance for culture-proven EOS with variables known at the start of antibiotic therapy. Machine learning was used in form of a random forest classifier. Results: One thousand six hundred eighty-five neonates treated for suspected infection were analyzed. Biomarkers were superior to clinical signs and RFs for prediction of culture-proven EOS. C-reactive protein and white blood cells were most important for the prediction of the culture result. Our full model achieved an area-under-the-receiver-operating-characteristic-curve of 83.41% (±8.8%) and an area-under-the-precision-recall-curve of 28.42% (±11.5%). The predictive performance of the model with RFs alone was comparable with random. Conclusions: Biomarkers have to be considered in algorithms for the management of neonates suspected of EOS. A 2-step approach with a screening tool for all neonates in combination with our model in the preselected population with an increased risk for EOS may have the potential to reduce the start of unnecessary antibiotics.

Published
2022

20. C-Reactive Protein, Procalcitonin, and White Blood Count to Rule Out Neonatal Early-onset Sepsis Within 36 Hours: A Secondary Analysis of the Neonatal Procalcitonin Intervention Study

Author

Stocker, Martin, van Herk, Wendy, El Helou, Salhab, Dutta, Sourabh, Schuerman, Frank A B A, van den Tooren-de Groot, Rita K, Wieringa, Jantien W, Janota, Jan, van der Meer-Kappelle, Laura H, Moonen, Rob, Sie, Sintha D, de Vries, Esther, Donker, Albertine E, Zimmerman, Urs, Schlapbach, Luregn J, de Mol, Amerik C, Hoffman-Haringsma, Angelique, Roy, Madan, Tomaske, Maren, Kornelisse, René F, van Gijsel, Juliette, Visser, Eline G, Plötz, Frans B, Heath, Paul, Achten, Niek B, Lehnick, Dirk, van Rossum, Annemarie M C, University of Zurich, and Stocker, Martin

Subjects
10036 Medical Clinic, 610 Medicine & health, 2725 Infectious Diseases, 2726 Microbiology (medical)
Published
2021

21. Machine Learning Used to Compare the Diagnostic Accuracy of Risk Factors, Clinical Signs and Biomarkers and to Develop a New Prediction Model for Neonatal Early-onset Sepsis

Author

Stocker, Martin, primary, Daunhawer, Imant, additional, van Herk, Wendy, additional, el Helou, Salhab, additional, Dutta, Sourabh, additional, Schuerman, Frank A. B. A., additional, van den Tooren-de Groot, Rita K., additional, Wieringa, Jantien W., additional, Janota, Jan, additional, van der Meer-Kappelle, Laura H., additional, Moonen, Rob, additional, Sie, Sintha D., additional, de Vries, Esther, additional, Donker, Albertine E., additional, Zimmerman, Urs, additional, Schlapbach, Luregn J., additional, de Mol, Amerik C., additional, Hoffmann-Haringsma, Angelique, additional, Roy, Madan, additional, Tomaske, Maren, additional, Kornelisse, René F., additional, van Gijsel, Juliette, additional, Plötz, Frans B., additional, Wellmann, Sven, additional, Achten, Niek B., additional, Lehnick, Dirk, additional, van Rossum, Annemarie M. C., additional, and Vogt, Julia E., additional

Published
2021
Full Text
View/download PDF

23. Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.

Author

Liu, Zheng, Julsgaard, Mette, Zhu, Xiao, Martin, Jennifer, Barclay, Murray L, Cranswick, Noel, Gibson, Peter R, Gearry, Richard B, van der Giessen, Janine, Connor, Susan J, Rosella, Ourania, Grosen, Anne, Toong, Catherine, Flanagan, Emma, Wieringa, Jantien W, Woude, C Janneke van der, Bell, Sally J, and Group, The CARINA Study

Abstract

Background and Aims For infants exposed in utero to anti-tumour necrosis factor-α [TNF] medications, it is advised that live-attenuated vaccinations be postponed until the drug is cleared, but little is known about time to clearance. To minimize delays before live-attenuated vaccination can be given, we aimed to develop a pharmacokinetic model to predict time-to-clearance in infants exposed during pregnancy. Methods We prospectively followed in utero infliximab/adalimumab-exposed infants of mothers with inflammatory bowel disease across four countries between 2011 and 2018. Infants with a detectable anti-TNF umbilical-cord level and at least one other blood sample during the first year of life were included. Results Overall, 107 infants were enrolled, including 166 blood samples from 71 infliximab-exposed infants and 77 samples from 36 adalimumab-exposed infants. Anti-TNF was detectable in 23% [ n  = 25] of infants at 6 months. At 12 months, adalimumab was not detected but 4% [ n  = 3] had detectable infliximab. A Bayesian forecasting method was developed using a one-compartment pharmacokinetic model. Model validation showed that the predicted clearing time was in accordance with the measured observations. A clinician-friendly online calculator was developed for calculating full anti-TNF clearing time: https://xiaozhu.shinyapps.io/antiTNFcalculator2/. Conclusions Almost one-quarter of infants born to mothers receiving anti-TNF during pregnancy have detectable anti-TNF at 6 months. To limit the time to live-attenuated vaccination in infants of mothers receiving anti-TNF during pregnancy, the results of a cord drug level at birth and a second sample ≥ 1 month thereafter can be used to estimate the time for full anti-TNF clearance in these children. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

24. C-Reactive Protein, Procalcitonin, and White Blood Count to Rule Out Neonatal Early-onset Sepsis Within 36 Hours: A Secondary Analysis of the Neonatal Procalcitonin Intervention Study

Author

Stocker, Martin, primary, van Herk, Wendy, additional, el Helou, Salhab, additional, Dutta, Sourabh, additional, Schuerman, Frank A B A, additional, van den Tooren-de Groot, Rita K, additional, Wieringa, Jantien W, additional, Janota, Jan, additional, van der Meer-Kappelle, Laura H, additional, Moonen, Rob, additional, Sie, Sintha D, additional, de Vries, Esther, additional, Donker, Albertine E, additional, Zimmerman, Urs, additional, Schlapbach, Luregn J, additional, de Mol, Amerik C, additional, Hoffman-Haringsma, Angelique, additional, Roy, Madan, additional, Tomaske, Maren, additional, F. Kornelisse, René, additional, van Gijsel, Juliette, additional, Visser, Eline G, additional, Plötz, Frans B, additional, Heath, Paul, additional, Achten, Niek B, additional, Lehnick, Dirk, additional, and van Rossum, Annemarie M C, additional

Published
2020
Full Text
View/download PDF

25. C-Reactive Protein, Procalcitonin, and White Blood Count to Rule Out Neonatal Early-onset Sepsis Within 36 Hours: A Secondary Analysis of the Neonatal Procalcitonin Intervention Study

Author

Stocker, Martin, Herk, Wendy van, Helou, Salhab el, Dutta, Sourabh, Schuerman, Frank A. B. A., van den Tooren-de Groot, Rita K., Wieringa, Jantien W., Meer-Kappelle, Laura H. van der, Sie, Sintha D., Vries, Esther de, Donker, Albertine E., Zimmermann, Urs, Schlapbach, Luregn J., Mol, Amerik C. de, Hoffman-Haringsma, Angelique, Roy, Madan, Tomaske, Maren, Kornelisse, René F., Gijsel, Juliette van, Visser, Eline G., Plötz, Frans B., Heath, Paul, Achten, Niek B., Lehnick, Dirk, Rossum, Annemarie M. C. van, Stocker, Martin, Herk, Wendy van, Helou, Salhab el, Dutta, Sourabh, Schuerman, Frank A. B. A., van den Tooren-de Groot, Rita K., Wieringa, Jantien W., Meer-Kappelle, Laura H. van der, Sie, Sintha D., Vries, Esther de, Donker, Albertine E., Zimmermann, Urs, Schlapbach, Luregn J., Mol, Amerik C. de, Hoffman-Haringsma, Angelique, Roy, Madan, Tomaske, Maren, Kornelisse, René F., Gijsel, Juliette van, Visser, Eline G., Plötz, Frans B., Heath, Paul, Achten, Niek B., Lehnick, Dirk, and Rossum, Annemarie M. C. van

Abstract

BACKGROUND Neonatal early-onset sepsis (EOS) is one of the main causes of global neonatal mortality and morbidity, and initiation of early antibiotic treatment is key. However, antibiotics may be harmful. METHODS We performed a secondary analysis of results from the Neonatal Procalcitonin Intervention Study, a prospective, multicenter, randomized, controlled intervention study. The primary outcome was the diagnostic accuracy of serial measurements of C-reactive protein (CRP), procalcitonin (PCT), and white blood count (WBC) within different time windows to rule out culture-positive EOS (proven sepsis). RESULTS We analyzed 1678 neonates with 10 899 biomarker measurements (4654 CRP, 2047 PCT, and 4198 WBC) obtained within the first 48 hours after the start of antibiotic therapy due to suspected EOS. The areas under the curve (AUC) comparing no sepsis vs proven sepsis for maximum values of CRP, PCT, and WBC within 36 hours were 0.986, 0.921, and 0.360, respectively. The AUCs for CRP and PCT increased with extended time frames up to 36 hours, but there was no further difference between start to 36 hours vs start to 48 hours. Cutoff values at 16 mg/L for CRP and 2.8 ng/L for PCT provided a sensitivity of 100% for discriminating no sepsis vs proven sepsis. CONCLUSIONS Normal serial CRP and PCT measurements within 36 hours after the start of empiric antibiotic therapy can exclude the presence of neonatal EOS with a high probability. The negative predictive values of CRP and PCT do not increase after 36 hours., + ID der Publikation: unilu_51625 + Sprache: Englisch + Letzte Aktualisierung: 2021-04-26 13:29:30

Published
2020

28. Congenital Cytomegalovirus

Author

Luck, Suzanne E., primary, Wieringa, Jantien W., additional, Blázquez-Gamero, Daniel, additional, Henneke, Philipp, additional, Schuster, Katharina, additional, Butler, Karina, additional, Capretti, Maria Grazia, additional, Cilleruelo, Maria José, additional, Curtis, Nigel, additional, Garofoli, Francesca, additional, Heath, Paul, additional, Iosifidis, Elias, additional, Klein, Nigel, additional, Lombardi, Giuseppina, additional, Lyall, Hermione, additional, Nieminen, Tea, additional, Pajkrt, Dasja, additional, Papaevangelou, Vassiliki, additional, Posfay-Barbe, Klara, additional, Puhakka, Laura, additional, Roilides, Emmanuel, additional, Rojo, Pablo, additional, Saavedra-Lozano, Jesús, additional, Shah, Teshri, additional, Sharland, Mike, additional, Saxen, Harri, additional, and Vossen, Ann C.T.M, additional

Published
2017
Full Text
View/download PDF

29. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns)

Author

Stocker, Martin, primary, van Herk, Wendy, additional, el Helou, Salhab, additional, Dutta, Sourabh, additional, Fontana, Matteo S, additional, Schuerman, Frank A B A, additional, van den Tooren-de Groot, Rita K, additional, Wieringa, Jantien W, additional, Janota, Jan, additional, van der Meer-Kappelle, Laura H, additional, Moonen, Rob, additional, Sie, Sintha D, additional, de Vries, Esther, additional, Donker, Albertine E, additional, Zimmerman, Urs, additional, Schlapbach, Luregn J, additional, de Mol, Amerik C, additional, Hoffman-Haringsma, Angelique, additional, Roy, Madan, additional, Tomaske, Maren, additional, Kornelisse, René F, additional, van Gijsel, Juliette, additional, Visser, Eline G, additional, Willemsen, Sten P, additional, van Rossum, Annemarie M C, additional, Bakry, A, additional, Dutta, S, additional, el Helou, S, additional, Kalaniti, K, additional, Pogorzelski, D, additional, Alliston, S, additional, Roy, M, additional, Grey, V, additional, Hauff, K, additional, Hill, S, additional, Kittanakom, S, additional, Janota, J, additional, Visnovska, M, additional, Fontana, M, additional, Lanz, N, additional, Stocker, M, additional, Glauser, D, additional, Zimmerman, U, additional, Tomaske, M, additional, Nelle, M, additional, Schlapbach, LJ, additional, Schuerman, FABA, additional, Sie, SD, additional, van Weissenbruch, MM, additional, van den Dungen, FAM, additional, Strik, M, additional, van den Tooren-de, HK, additional, van Rossum, Groot A, additional, Batstra, M, additional, van der Meer-Kappelle, LH, additional, de Vries, E, additional, de Mol, AC, additional, Bolt-Wieringa, J, additional, Stok, Daniel, additional, Moonen, R, additional, Donker, S, additional, van Gijsel, J, additional, Gondriet, IPE, additional, van Herk, W, additional, Hoekstein, S, additional, Hofhuis, M, additional, Hop, W, additional, de Ligt, L, additional, Manai, B, additional, Kornelisse, R, additional, de Rijke, Y, additional, van Rossum, A, additional, Siiskonen, S, additional, van der Velden, J, additional, Visser, EG, additional, van Wijk, J Asch, additional, Willemsen, S, additional, van der Geijn, GJ, additional, Haringsma, A, additional, Andriessen, PA, additional, Broeren, MAC, additional, and Donker, A, additional

Published
2017
Full Text
View/download PDF

32. Machine Learning Used to Compare the Diagnostic Accuracy of Risk Factors, Clinical Signs and Biomarkers and to Develop a New Prediction Model for Neonatal Early-onset Sepsis.

Author

Stocker M, Daunhawer I, van Herk W, El Helou S, Dutta S, Schuerman FABA, van den Tooren-de Groot RK, Wieringa JW, Janota J, van der Meer-Kappelle LH, Moonen R, Sie SD, de Vries E, Donker AE, Zimmerman U, Schlapbach LJ, de Mol AC, Hoffmann-Haringsma A, Roy M, Tomaske M, Kornelisse RF, van Gijsel J, Plötz FB, Wellmann S, Achten NB, Lehnick D, van Rossum AMC, and Vogt JE

Subjects
Anti-Bacterial Agents therapeutic use, C-Reactive Protein analysis, Female, Humans, Infant, Infant, Newborn, Male, Neonatal Sepsis drug therapy, Prospective Studies, ROC Curve, Risk Factors, Biomarkers blood, Machine Learning, Neonatal Sepsis diagnosis
Abstract

Background: Current strategies for risk stratification and prediction of neonatal early-onset sepsis (EOS) are inefficient and lack diagnostic performance. The aim of this study was to use machine learning to analyze the diagnostic accuracy of risk factors (RFs), clinical signs and biomarkers and to develop a prediction model for culture-proven EOS. We hypothesized that the contribution to diagnostic accuracy of biomarkers is higher than of RFs or clinical signs., Study Design: Secondary analysis of the prospective international multicenter NeoPInS study. Neonates born after completed 34 weeks of gestation with antibiotic therapy due to suspected EOS within the first 72 hours of life participated. Primary outcome was defined as predictive performance for culture-proven EOS with variables known at the start of antibiotic therapy. Machine learning was used in form of a random forest classifier., Results: One thousand six hundred eighty-five neonates treated for suspected infection were analyzed. Biomarkers were superior to clinical signs and RFs for prediction of culture-proven EOS. C-reactive protein and white blood cells were most important for the prediction of the culture result. Our full model achieved an area-under-the-receiver-operating-characteristic-curve of 83.41% (±8.8%) and an area-under-the-precision-recall-curve of 28.42% (±11.5%). The predictive performance of the model with RFs alone was comparable with random., Conclusions: Biomarkers have to be considered in algorithms for the management of neonates suspected of EOS. A 2-step approach with a screening tool for all neonates in combination with our model in the preselected population with an increased risk for EOS may have the potential to reduce the start of unnecessary antibiotics., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2022
Full Text
View/download PDF

33. [Congenital CMV infections].

Author

Wieringa JW, de Vries JJ, and Murk JL

Subjects
Amniotic Fluid virology, Antiviral Agents therapeutic use, Chorioretinitis congenital, Chorioretinitis virology, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections drug therapy, Cytomegalovirus Infections prevention & control, DNA, Viral analysis, Female, Hearing Loss, Sensorineural congenital, Humans, Infant, Newborn, Male, Pregnancy, Pregnancy Complications, Infectious diagnosis, Pregnancy Complications, Infectious drug therapy, Pregnancy Complications, Infectious prevention & control, Cytomegalovirus Infections congenital, Hearing Loss, Sensorineural virology
Abstract

Only 10-15% of neonates with congenital cytomegalovirus infection have symptoms at birth. The most common symptoms are intrauterine growth retardation, microcephaly, petechiae, jaundice, hepatosplenomegaly, intracranial abnormalities, ophthalmological abnormalities and hearing loss. Symptomatic and asymptomatic CMV infections can both have long-term effects. CMV infection during pregnancy is diagnosed using a blood test and possible testing of the amniotic fluid for viral DNA. Infection of the fetus may be prevented by treating the mother with CMV hyperimmune globulin. In the neonate a diagnosis can be made by viral culture or PCR in urine. PCR in saliva could be an alternative. Blood testing is of limited value. If symptoms of CMV infection occur in the neonate, such as petechiae, microcephaly, central nervous system abnormalities, sensorineural hearing loss or chorioretinitis, antiviral treatment should be considered. Long-term follow-up is advisable because of the possibility of delayed-onset hearing loss and chorioretinitis.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results